J Gebauer1, H Lehnert1, S M Schmid1, C Spix2, A Stein3, T Langer4. 1. Medizinische Klinik 1, Abteilung für Endokrinologie, Diabetologie und Stoffwechselmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland. 2. Deutsches Kinderkrebsregister, Institut für Medizinische Biometrie, Epidemiologie und Informatik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Deutschland. 3. Universitäres Cancer Center Hamburg (UCCH), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. 4. Klinik für Kinder- und Jugendmedizin, Bereich pädiatrische Hämatologie und Onkologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland. thorsten.langer@uksh.de.
Abstract
BACKGROUND: Childhood cancer survivors are at risk of cancer- and treatment-related chronic health conditions. Since these sequelae may occur years after the end of treatment, many patients are already adults and have completed pediatric oncological care. Thus, successful transition is essential in order to ensure long-term surveillance. OBJECTIVES: The present review outlines the most frequent late effects of childhood cancer treatment. Moreover, difficulties in transition of these patients are discussed and interdisciplinary models of care are presented. RESULTS: Late effects following childhood cancer treatment occur in over two thirds of patients 30 years after the end of the oncological treatment and can affect different organs. The most frequent sequelae are endocrine disturbances, cardiac conditions, and subsequent neoplasms. Many late effects are effectively manageable if detected early. This necessitates an interdisciplinary approach as well as life-long surveillance. CONCLUSIONS: Transition from pediatric to internal medicine care as well as a change in the focus of care, shifting from relapse centered follow-up to late-effects centered surveillance, constitute a special challenge for a successful transition of long-term childhood cancer survivors. Specialized late-effects survivorship clinics offering interdisciplinary care from pediatric oncologists, specialists of internal medicine, and further disciplines enable the early diagnosis and treatment of late-effects.
BACKGROUND: Childhood cancer survivors are at risk of cancer- and treatment-related chronic health conditions. Since these sequelae may occur years after the end of treatment, many patients are already adults and have completed pediatric oncological care. Thus, successful transition is essential in order to ensure long-term surveillance. OBJECTIVES: The present review outlines the most frequent late effects of childhood cancer treatment. Moreover, difficulties in transition of these patients are discussed and interdisciplinary models of care are presented. RESULTS: Late effects following childhood cancer treatment occur in over two thirds of patients 30 years after the end of the oncological treatment and can affect different organs. The most frequent sequelae are endocrine disturbances, cardiac conditions, and subsequent neoplasms. Many late effects are effectively manageable if detected early. This necessitates an interdisciplinary approach as well as life-long surveillance. CONCLUSIONS: Transition from pediatric to internal medicine care as well as a change in the focus of care, shifting from relapse centered follow-up to late-effects centered surveillance, constitute a special challenge for a successful transition of long-term childhood cancer survivors. Specialized late-effects survivorship clinics offering interdisciplinary care from pediatric oncologists, specialists of internal medicine, and further disciplines enable the early diagnosis and treatment of late-effects.
Entities:
Keywords:
Aftercare, long-term; Delivery of health care; Endocrine system diseases; Interdisciplinary communication; Models of care
Authors: Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer Journal: Lancet Oncol Date: 2015-03 Impact factor: 41.316
Authors: S C Clement; L C M Kremer; F A Verburg; J H Simmons; M Goldfarb; R P Peeters; E K Alexander; E Bardi; E Brignardello; L S Constine; C A Dinauer; V M Drozd; F Felicetti; E Frey; A Heinzel; M M van den Heuvel-Eibrink; S A Huang; T P Links; K Lorenz; R L Mulder; S J Neggers; E J M Nieveen van Dijkum; K C Oeffinger; R R van Rijn; S A Rivkees; C M Ronckers; A B Schneider; R Skinner; J D Wasserman; T Wynn; M M Hudson; P C Nathan; H M van Santen Journal: Cancer Treat Rev Date: 2017-11-14 Impact factor: 12.111
Authors: Emily S Tonorezos; Dana Barnea; Richard J Cohn; Monica S Cypriano; Brice C Fresneau; Riccardo Haupt; Lars Hjorth; Yasushi Ishida; Jarmila Kruseova; Claudia E Kuehni; Purna A Kurkure; Thorsten Langer; Paul C Nathan; Jane E Skeen; Roderick Skinner; Nurdan Tacyildiz; Marry M van den Heuvel-Eibrink; Jeanette F Winther; Melissa M Hudson; Kevin C Oeffinger Journal: J Clin Oncol Date: 2018-06-06 Impact factor: 44.544
Authors: E Brignardello; F Felicetti; A Castiglione; P Chiabotto; A Corrias; F Fagioli; G Ciccone; G Boccuzzi Journal: Eur J Endocrinol Date: 2013-02-20 Impact factor: 6.664
Authors: Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Smita Bhatia; Wendy Landier; Gill Levitt; Louis S Constine; W Hamish Wallace; Flora E van Leeuwen; Cécile M Ronckers; Tara O Henderson; Mary Dwyer; Roderick Skinner; Kevin C Oeffinger Journal: Lancet Oncol Date: 2013-12 Impact factor: 41.316
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816